B. Kassler Taub - 28 Feb 2023 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Role
SVP, Regulatory & QA
Signature
/s/ Kenneth B. Kassler-Taub, M.D.
Issuer symbol
LXRX
Transactions as of
28 Feb 2023
Net transactions value
-$41,486
Form type
4
Filing time
01 Mar 2023, 15:51:47 UTC
Previous filing
13 Feb 2023
Next filing
12 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXRX Common Stock Options Exercise +18,243 +21% 104,100 28 Feb 2023 Direct F1
transaction LXRX Common Stock Options Exercise +7,086 +6.8% 111,186 28 Feb 2023 Direct F1
transaction LXRX Common Stock Options Exercise +27,557 +25% 138,743 28 Feb 2023 Direct F1
transaction LXRX Common Stock Tax liability $41,486 -19,118 -14% $2.17 119,625 28 Feb 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LXRX Restricted Stock Units Options Exercise -18,243 -100% 0 28 Feb 2023 Common Stock 18,243 Direct F1, F3
transaction LXRX Restricted Stock Units Options Exercise -7,086 -50% 7,087 28 Feb 2023 Common Stock 7,086 Direct F1, F3
transaction LXRX Restricted Stock Units Options Exercise -27,557 -33% 55,113 28 Feb 2023 Common Stock 27,557 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock.
F2 Withholding of a portion of issued shares by the Company in satisfaction of shareholder's tax withholding obligations with respect thereto.
F3 Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.